Mauna Kea Technologies manufactures Cellvizio Lab, confocal probe based imaging system, providing cellular-level images with minimal invasiveness for longitudinal studies.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Nov 14, 2023
The xCELLigence RTCA eSight enables simultaneous real time biosensor impedance-based and...
NanoCellect webinar: Plant Potential - Gentle Cell Sorting for Enhanced Plant Biology Workflows
Nov 3, 2023
Gentle cell sorting is a useful tool to increase the efficiency of plant biology workflows that include gene...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Nov 2, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
Oct 31, 2023
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Oct 30, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
De novo design of a biologically active amyloid
Feb 5, 2018
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. Gallardo et al. designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. They found that amyloid toxicity is observed only in cells that both express VEGFR2 and are dependent on VEGFR2 activity for survival. Thus, amyloid toxicity here appears to be both protein-specific and conditional—determined by VEGFR2 loss of function in a biological context in which target protein function is essential.
Get more info
Brand profile
